
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4328314/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cluster randomised, controlled, triple-blind trial assessing the efficacy of intranasally administered virus-neutralising bovine colostrum supplement in preventing SARS-CoV-2 infection in household contacts of SARS-CoV-2-positive individuals: a study protocol. Trials, 2022, 23, 92.	0.7	4
2	The 1st year of the COVID-19 epidemic in Estonia: a population-based nationwide sequential/consecutive cross-sectional study. Public Health, 2022, 205, 150-156.	1.4	4
3	Long-term mortality following SARS-CoV-2 infection: A national cohort study from Estonia. Lancet Regional Health - Europe, The, 2022, 18, 100394.	3.0	22
4	Cervical Cancer in the Baltic States: Can Intelligent and Personalised Cancer Screening Change the Situation?. Acta Medica Lituanica, 2022, 29, 18.	0.2	2
5	A Multistage Process Model of How a Person Who Currently Injects Drugs Comes to Assist Persons Who Do not Inject with Their First Injections. Frontiers in Sociology, 2021, 6, 619560.	1.0	6
6	Cervical cancer screening patterns among HIV-positive women in Estonia: a population-based retrospective cohort study. BMC Cancer, 2021, 21, 350.	1.1	3
7	Rapid point-of-care (POC) testing for Hepatitis C antibodies in a very high prevalence setting: persons injecting drugs in Tallinn, Estonia. Harm Reduction Journal, 2021, 18, 39.	1.3	5
8	Prevalence of chronic conditions and multimorbidity in Estonia: a population-based cross-sectional study. BMJ Open, 2021, 11, e049045.	0.8	10
9	Physical-mental health comorbidity: A population-based cross-sectional study. PLoS ONE, 2021, 16, e0260464.	1.1	10
10	Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. Eurosurveillance, 2021, 26, .	3.9	4
11	Seroprevalence of SARSâ€CoVâ€2 antibodies among pregnant women in Estonia: A call for epidemiological studies. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 1736-1737.	1.3	2
12	The fentanyl epidemic in Estonia: factors in its evolution and opportunities for a comprehensive public health response, a scoping review. International Journal of Drug Policy, 2020, 81, 102757.	1.6	20
13	Trends in opioid prescribing in Estonia (2011â€2017). Pharmacology Research and Perspectives, 2020, 8, e00577.	1.1	4
14	Presenting a conceptual framework for an HIV prevention and care continuum and assessing the feasibility of empirical measurement in Estonia: A case study. PLoS ONE, 2020, 15, e0240224.	1.1	2
15	Prevalence of injecting drug use in Estonia 2010–2015: a capture-recapture study. Harm Reduction Journal, 2019, 16, 19.	1.3	7
16	Implementing an Updated "Break the Cycle―Intervention to Reduce Initiating Persons into Injecting Drug Use in an Eastern European and a US "opioid epidemic―Setting. AIDS and Behavior, 2019, 23, 2304-2314.	1.4	24
17	The fentanyl epidemic in Estonia: opportunities for a comprehensive public health response. Lancet Psychiatry,the, 2019, 6, 985.	3.7	10
18	Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, FO-VAS, and time-trade-off: results from the ICUROS. Quality of Life Research, 2018, 27, 707-716	1.5	36

#	Article	IF	CITATIONS
19	Differences in risk behaviours and HIV status between primary amphetamines and opioid injectors in Estonia and Russia. International Journal of Drug Policy, 2018, 53, 96-105.	1.6	8
20	Preventing Injection Drug use Initiation: State of the Evidence and Opportunities for the Future. Journal of Urban Health, 2018, 95, 91-98.	1.8	39
21	Perceived effectiveness of antiretroviral therapy, self-rated health and treatment adherence among HIV-positive people who inject drugs in Estonia. International Journal of STD and AIDS, 2018, 29, 13-22.	0.5	6
22	Polydrug Use and Heterogeneity in HIV Risk Among People Who Inject Drugs in Estonia and Russia: A Latent Class Analysis. AIDS and Behavior, 2018, 22, 1329-1340.	1.4	25
23	Treatment of chlamydia and gonorrhoea, compliance with treatment guidelines and factors associatedwith non-compliant prescribing: findings form a cross-sectional study. Sexually Transmitted Infections, 2018, 94, 298-303.	0.8	8
24	Quality of life for up to 18Âmonths after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS. Osteoporosis International, 2018, 29, 557-566.	1.3	88
25	Effects of Counselling on Adherence to Antiretroviral Treatment Among People with HIV in Estonia: A Randomized Controlled Trial. AIDS and Behavior, 2018, 22, 224-233.	1.4	9
26	Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000–2017: Protective effects of non-injecting drug use. Drug and Alcohol Dependence, 2018, 192, 74-79.	1.6	18
27	Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012–2016. Drugs - Real World Outcomes, 2018, 5, 129-136.	0.7	9
28	Frequency and factors associated with providing injection initiation assistance in Tallinn, Estonia. Drug and Alcohol Dependence, 2018, 188, 64-70.	1.6	17
29	Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015. BMC Infectious Diseases, 2018, 18, 339.	1.3	9
30	Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. Journal of Medical Virology, 2018, 90, 1779-1783.	2.5	4
31	Another frontier for harm reduction: contraceptive needs of females who inject drugs in Estonia, a cross-sectional study. Harm Reduction Journal, 2018, 15, 10.	1.3	6
32	Eastern Europe and Central Asia, Specific Characteristics of HIV/AIDS Epidemic. , 2018, , 473-477.		0
33	Engagement in HIV care and its correlates among people who inject drugs in St Petersburg, Russian Federation and Kohtla-J¤ve, Estonia. Addiction, 2017, 112, 1421-1431.	1.7	23
34	The impact of comorbidities on hip fracture mortality: a retrospective population-based cohort study. Archives of Osteoporosis, 2017, 12, 76.	1.0	15
35	Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage. Vaccine, 2017, 35, 6329-6335.	1.7	9
36	The Role of Internalized Stigma in the Disclosure of Injecting Drug Use Among People Who Inject Drugs and Self-Report as HIV-Positive in Kohtla-Jäve, Estonia. AIDS and Behavior, 2017, 21, 1034-1043.	1.4	10

#	Article	IF	CITATIONS
37	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduction Journal, 2017, 14, 19.	1.3	33
38	Suicidal Behavior Among People Living with HIV (PLHIV) in Medical Care in Estonia and Factors Associated with Receiving Psychological Treatment. AIDS and Behavior, 2017, 21, 1709-1716.	1.4	9
39	Prevalence and genotypes of GBVâ€C and its associations with HIV infection among persons who inject drugs in Eastern Europe. Journal of Medical Virology, 2017, 89, 632-638.	2.5	18
40	Qualitative interviews with healthcare staff in four European countries to inform adaptation of an intervention to increase chlamydia testing. BMJ Open, 2017, 7, e017528.	0.8	3
41	The impact of hip fracture on mortality in Estonia: a retrospective population-based cohort study. BMC Musculoskeletal Disorders, 2017, 18, 243.	0.8	15
42	Using data from respondent-driven sampling studies to estimate the number of people who inject drugs: Application to the Kohtla-JÃ ¤ ve region of Estonia. PLoS ONE, 2017, 12, e0185711.	1.1	4
43	HIV prevalence and gender differences among new injection-drug-users in Tallinn, Estonia: A persisting problem in a stable high prevalence epidemic. PLoS ONE, 2017, 12, e0170956.	1.1	11
44	People living with HIV in Estonia: engagement in HIV care in 2013. Eurosurveillance, 2016, 21, .	3.9	3
45	Quality of life, resource use, and costs related to hip fracture in Estonia. Osteoporosis International, 2016, 27, 2555-2566.	1.3	17
46	T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral Immunology, 2016, 29, 464-470.	0.6	8
47	Screening for genital chlamydia infection. The Cochrane Library, 2016, 2016, CD010866.	1.5	47
48	Changes in chlamydia control activities in Europe between 2007 and 2012: a cross-national survey. European Journal of Public Health, 2016, 26, 382-388.	0.1	22
49	Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infection, Genetics and Evolution, 2016, 43, 83-85.	1.0	7
50	Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical Microbiology and Immunology, 2016, 205, 231-239.	2.6	7
51	Internalized HIV and Drug Stigmas: Interacting Forces Threatening Health Status and Health Service Utilization Among People with HIV Who Inject Drugs in St. Petersburg, Russia. AIDS and Behavior, 2016, 20, 85-97.	1.4	60
52	A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PLoS ONE, 2016, 11, e0156850.	1.1	3
53	Comparison of subset selection methods in linear regression in the context of health-related quality of life and substance abuse in Russia. BMC Medical Research Methodology, 2015, 15, 71.	1.4	52
54	Non-fatal overdoses and related risk factors among people who inject drugs in St. Petersburg, Russia and Kohtla-J¤ve, Estonia. BMC Public Health, 2015, 15, 1255.	1.2	32

#	Article	IF	CITATIONS
55	HTLV-1/2 is rare among Eastern-European intravenous drug users (IDUs). Retrovirology, 2015, 12, .	0.9	ο
56	Genital Chlamydia Prevalence in Europe and Non-European High Income Countries: Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0115753.	1.1	57
57	The incidence of hip fractures in Estonia, 2005–2012. Osteoporosis International, 2015, 26, 77-84.	1.3	15
58	HIV research productivity and structural factors associated with HIV research output in European Union countries: a bibliometric analysis. BMJ Open, 2015, 5, e006591-e006591.	0.8	17
59	Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users. Infection, Genetics and Evolution, 2015, 30, 175-180.	1.0	12
60	A tale of two cities: Stigma and health outcomes among people with HIV who inject drugs in St. Petersburg, Russia and Kohtla-Jäve, Estonia. Social Science and Medicine, 2015, 130, 154-161.	1.8	45
61	Adherence to Antiretroviral Medications Among Persons Who Inject Drugs in Transitional, Low and Middle Income Countries: An International Systematic Review. AIDS and Behavior, 2015, 19, 575-583.	1.4	31
62	An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. International Journal of Drug Policy, 2015, 26, 1056-1063.	1.6	33
63	Disseminated Giant Hyperkeratotic Porokeratosis and Treatment with Acitretin: A Case Report. Acta Dermato-Venereologica, 2015, 95, 241-242.	0.6	7
64	The prevalence of genital warts in the Baltic countries: findings from national cross-sectional surveys in Estonia, Latvia and Lithuania. Sexually Transmitted Infections, 2015, 91, 55-60.	0.8	5
65	Combined prevention for persons who inject drugs in the HIV epidemic in a transitional country: the case of Tallinn, Estonia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 105-111.	0.6	14
66	Behavioral Interventions to Reduce Sexual Risk Behavior in Adults with HIV/AIDS Receiving HIV Care: A Systematic Review. AIDS Patient Care and STDs, 2015, 29, 288-298.	1.1	11
67	Provision of chlamydia testing, and training of primary health care staff about chlamydia testing, across four European countries. BMC Public Health, 2014, 14, 1147.	1.2	6
68	Association Between HIV-1 Tropism and CCR5 Human Haplotype E in a Caucasian Population. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 239-244.	0.9	5
69	Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe. Aids, 2014, 28, 1657-1664.	1.0	8
70	The HIV Epidemic in Eastern Europe and Central Asia. Current HIV/AIDS Reports, 2014, 11, 168-176.	1.1	84
71	Prevalence of IGRA-positivity and risk factors for tuberculosis among injecting drug users in Estonia and Latvia. International Journal of Drug Policy, 2014, 25, 175-178.	1.6	5
72	Non-cancer morbidity among Estonian Chernobyl cleanup workers: a register-based cohort study. BMJ Open, 2014, 4, e004516.	0.8	19

#	Article	IF	CITATIONS
73	HIV testing and counselling in Estonian prisons, 2012 to 2013: aims, processes and impacts. Eurosurveillance, 2014, 19, 20970.	3.9	6
74	The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia. BMC Infectious Diseases, 2013, 13, 304.	1.3	9
75	Is the HCV–HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. Drug and Alcohol Dependence, 2013, 132, 172-181.	1.6	40
76	Developing an adherence support intervention for patients on antiretroviral therapy in the context of the recent IDU-driven HIV/AIDS epidemic in Estonia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 863-873.	0.6	12
77	Socio-demographic factors, health risks and harms associated with early initiation of injection among people who inject drugs in Tallinn, Estonia: Evidence from cross-sectional surveys. International Journal of Drug Policy, 2013, 24, 150-155.	1.6	18
78	Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infection, Genetics and Evolution, 2013, 20, 78-82.	1.0	33
79	A decline in the prevalence of injecting drug users in Estonia, 2005–2009. International Journal of Drug Policy, 2013, 24, 312-318.	1.6	21
80	Risk for Heterosexual HIV Transmission Among Non-Injecting Female Partners of Injection Drug Users in Estonia. AIDS and Behavior, 2013, 17, 879-888.	1.4	7
81	Non-fatal injuries resulting in activity limitations in Estonia—risk factors and association with the incidence of chronic conditions and quality of life: a retrospective study among the population aged 20–79. BMJ Open, 2013, 3, e002695.	0.8	3
82	Years of potential life lost due to HIV infection and associated factors based on national HIV surveillance data in Latvia, 1991–2010. Scandinavian Journal of Infectious Diseases, 2013, 45, 140-146.	1.5	2
83	Incidence of Cervical Intraepithelial Neoplasia in Estonia. Journal of Lower Genital Tract Disease, 2013, 17, 129-136.	0.9	4
84	30 Years on Selected Issues in the Prevention of HIV among Persons Who Inject Drugs. Advances in Preventive Medicine, 2013, 2013, 1-10.	1.1	17
85	Changes in high-risk sexual behaviour among Estonian adults between 1996 and 2006. Sexually Transmitted Infections, 2013, 89, 91-97.	0.8	2
86	CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLoS ONE, 2013, 8, e70561.	1.1	4
87	Condom use and partnership intimacy among drug injectors and their sexual partners in Estonia: Table 1. Sexually Transmitted Infections, 2012, 88, 58-62.	0.8	24
88	Multiple routes of drug administration and HIV risk among injecting drug users. Journal of Substance Abuse Treatment, 2012, 42, 413-420.	1.5	9
89	Antiretroviral therapy (ART) adherence and correlates to nonadherence among people on ART in Estonia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 1470-1479.	0.6	21
90	Antiretroviral therapy (ART) adherence and correlates to non-adherence among people on ART in Estonia. Retrovirology, 2012, 9, .	0.9	0

#	Article	IF	CITATIONS
91	Enhanced tuberculosis case detection among substitution treatment patients: a randomized controlled trial. BMC Research Notes, 2011, 4, 192.	0.6	7
92	Assessing non-response to a mailed health survey including self-collection of biological material. European Journal of Public Health, 2011, 21, 538-542.	0.1	20
93	Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia. BMC Public Health, 2011, 11, 517.	1.2	26
94	Estonia at the Threshold of the Fourth Decade of the AIDS Era in Europe. AIDS Research and Human Retroviruses, 2011, 27, 841-851.	0.5	23
95	Self-reported activity limitations among the population aged 20-79 in Estonia: a cross-sectional study. European Journal of Public Health, 2011, 21, 49-55.	0.1	7
96	Evaluating Recruitment among Female Sex Workers and Injecting Drug Users at Risk for HIV Using Respondent-driven Sampling in Estonia. Journal of Urban Health, 2010, 87, 304-317.	1.8	43
97	HIV infection and risk behaviour of primary fentanyl and amphetamine injectors in Tallinn, Estonia: Implications for intervention. International Journal of Drug Policy, 2010, 21, 56-63.	1.6	50
98	Population-based type-specific prevalence of high-risk human papillomavirus infection in Estonia. BMC Infectious Diseases, 2010, 10, 63.	1.3	21
99	Services integration for injection drug users on antiretroviral therapy for management of HIV epidemic in Estonia. Retrovirology, 2010, 7, .	0.9	0
100	CCL3L1Copy Number Is a Strong Genetic Determinant of HIV Seropositivity in Caucasian Intravenous Drug Users. Journal of Infectious Diseases, 2010, 201, 730-739.	1.9	28
101	Trends in the epidemiology of bacterial sexually transmitted infections in eastern Europe, 1995-2005. Sexually Transmitted Infections, 2010, 86, 6-14.	0.8	38
102	Emergent properties of HIV risk among injection drug users in Tallinn, Estonia: synthesis of individual and neighbourhood-level factors. Sexually Transmitted Infections, 2010, 86, iii79-iii84.	0.8	12
103	European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sexually Transmitted Infections, 2010, 86, 427-432.	0.8	53
104	Should Pharmacists have a Role in Harm Reduction Services for IDUs? A Qualitative Study in Tallinn, Estonia. Journal of Urban Health, 2009, 86, 918-928.	1.8	11
105	Informed recruitment in partner studies of HIV transmission: an ethical issue in couples research. BMC Medical Ethics, 2009, 10, 14.	1.0	3
106	Comparison of injecting drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn, Estonia. Harm Reduction Journal, 2009, 6, 3.	1.3	23
107	Factors influencing quality of life of people living with HIV in Estonia: a crossâ€sectional survey. Journal of the International AIDS Society, 2009, 12, 13-13.	1.2	30
108	Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 851-857.	0.6	19

#	Article	IF	CITATIONS
109	The Trends and Risk Factors for Hepatitis B Occurrence in Estonia. Central European Journal of Public Health, 2009, 17, 108-111.	0.4	7
110	A study on HIV and hepatitis C virus among commercial sex workers in Tallinn. Sexually Transmitted Infections, 2008, 84, 189-191.	0.8	30
111	High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs. Journal of Public Health, 2008, 30, 119-125.	1.0	41
112	The prevalence of chlamydial infection in Estonia: a population-based survey. International Journal of STD and AIDS, 2008, 19, 455-458.	0.5	16
113	Quality of Life of People Living with HIV and AIDS in Estonia. Central European Journal of Public Health, 2008, 16, 111-115.	0.4	5
114	High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia. International Journal of STD and AIDS, 2007, 18, 41-46.	0.5	34
115	The HIV prevention needs of injection drug users in Estonia. International Journal of STD and AIDS, 2007, 18, 389-391.	0.5	27
116	Estimating injection drug use prevalence using state wide administrative data sources: Estonia, 2004. Addiction Research and Theory, 2007, 15, 411-424.	1.2	25
117	High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. Aids, 2006, 20, 2120-2123.	1.0	61
118	HIV epidemic in Estonia in the third decade of the AIDS era. Scandinavian Journal of Infectious Diseases, 2006, 38, 181-186.	1.5	17
119	Sex work in Tallinn, Estonia: the sociospatial penetration of sex work into society. Sexually Transmitted Infections, 2006, 82, 348-353.	0.8	24
120	Barriers to effective STI screening in a post-Soviet society: results from a qualitative study. Sexually Transmitted Infections, 2006, 82, 323-326.	0.8	6
121	Surveillance of HIV, Hepatitis B Virus, and Hepatitis C Virus in an Estonian Injection Drug–Using Population: Sensitivity and Specificity of Testing Syringes for Public Health Surveillance. Journal of Infectious Diseases, 2006, 193, 455-457.	1.9	20
122	Laboratory Diagnosis of Sexually Transmitted Infections in Estonia in 2001–2002: Shortcomings With Impact on Diagnostic Quality and Surveillance. Sexually Transmitted Diseases, 2005, 32, 759-764.	0.8	13
123	Dengue encephalitis in a Swedish traveller returning from Thailand. Scandinavian Journal of Infectious Diseases, 2005, 37, 776-778.	1.5	16
124	The Burden of Infection with Herpes Simplex Virus Type 1 and Type 2: Seroprevalence Study in Estonia. Scandinavian Journal of Infectious Diseases, 2004, 36, 727-732.	1.5	10
125	Atypical genital herpes: Report of five cases. Scandinavian Journal of Infectious Diseases, 2004, 36, 37-39.	1.5	10
126	Treatment of Sexually Transmitted Diseases in Estonia. Sexually Transmitted Diseases, 2004, 31, 631-635.	0.8	6

#	Article	IF	CITATIONS
127	Syphilis as a Social Disease: Experience from the Post-Communist Transition Period in Estonia. International Journal of STD and AIDS, 2004, 15, 662-668.	0.5	8
128	Syphilis as a social disease: experience from the post-communist transition period in Estonia. International Journal of STD and AIDS, 2004, 15, 662-668.	0.5	5
129	Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. Sexually Transmitted Infections, 2003, 79, 286-290.	0.8	87
130	Genital mycoplasmas, including Mycoplasma genitalium, as sexually transmitted agents. International Journal of STD and AIDS, 2002, 13, 79-85.	0.5	66
131	The role of injection drug use in the emergence of human immunodeficiency virus infection in Estonia. International Journal of Infectious Diseases, 2002, 6, 23-27.	1.5	40
132	A Case???Control Study of Beliefs and Behaviors Associated With Sexually Transmitted Disease Occurrence in Estonia. Sexually Transmitted Diseases, 2001, 28, 624-629.	0.8	19
133	Sexually transmitted infections in Estonia—syndromic management of urethritis in a European country?. International Journal of STD and AIDS, 2001, 12, 493-498.	0.5	7
134	Sexually transmitted diseases in Estonia: past and present. International Journal of STD and AIDS, 1997, 8, 446-450.	0.5	26